Eli Lilly sees Alzheimer's drug development beyond amyloid beta targeting

jetcityimage/iStock Editorial via Getty Images

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli Lilly (NYSE:LLY) is looking at other targets as well.

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its